Taubman Institute Call for Nominations
The A. Alfred Taubman Medical Research Institute is seeking qualified candidates to fill a vacancy in its Taubman Scholars Program.
The Taubman Scholars Program is the core initiative of the Taubman Institute, providing University of Michigan senior physician-scientists with financial support designed to foster translational research. The goal of the program is to accelerate the pace with which laboratory discoveries are transformed into new patient treatments.
Taubman Scholars receive grants of $150,000 per year for three years. Although the Taubman Institute provides grants for research on a wide spectrum of diseases, it has core areas of inquiry: cancer, cardiovascular disease, diabetes and other metabolic diseases, and neurological disorders. It also seeks to fund scientists working in the emerging technologies of advanced imaging and surgical devices, who will collaborate with other Scholars to allow for the rapid translation of new ideas into actual therapies.
Eligibility is restricted to:
• University of Michigan senior faculty, associate or full professors
• Holders of medical degrees (an M.D. or M.D./Ph.D.)
• Clinician-scientists, individuals who are conducting basic research while maintaining an active clinical practice.
• Scientists whose research focuses on translational research
The deadline for applications is April 1, 2013. All applications should be submitted electronically using this form on the Taumbman Institute website.
Once an application is received, it will be reviewed by the Director of the Taubman Institute to ensure applicant eligibility before being submitted to the Taubman Institute Scientific Advisory Board for evaluation. The Scientific Advisory Board, comprised of nationally prominent clinician-scientists, will make funding recommendations to the Director and to the members of the Governing Council of the Taubman Institute, who possess the ultimate grant-making authority.
The criteria for making such decisions include:
• Quality and scope of the proposed research from applicants who meet all eligibility requirements
• Translational nature of the proposed research
• The “high risk, high reward” nature of the proposed research, which would render it unlikely to receive funding from traditional sources
• Its alignment with the current scientific objectives of the Institute, as determined by the Director and Governing Council
Barring any unforeseen delays, the effective date of this grant will be July 1, 2013.
A new Taubman Scholar is responsible for opening an account in his or her Medical School department to which the grant funding will be transferred. It is the responsibility of that department to monitor all expenses for which this grant is used to make certain that they are in accordance with all University of Michigan policies and regulations.
Taubman-sponsored research offers breast tumor insights
Taubman Emerging Scholar Dr. Scott Tomlins has authored a new study about phyllodes tumors.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
Familial ALS affects generations
Detroit News column featuring Dr. Eva Feldman depicts the toll of the disease on one Metro Detroit family
news & events
In the News
PBS series features institute director on Jan. 18
"The Embrace of Aging," a documentary series airing Sundays at 2:30 p.m. on Detroit Public Televsion, features Taubman Institute Director Eva Feldman, M.D., Ph.D. and her landmark ALS stem cell trial in the Jan. 18 episode.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.